Half Yearly Report

RNS Number : 0232R

Clinical Computing PLC

13 August 2010

 



CLINICAL COMPUTING PLC

HALF YEAR RESULTS FOR THE SIX MONTHS TO 30 JUNE 2010

Clinical Computing Plc ("the Group"), the international developer of clinical information systems for the healthcare market and developer of programme management software, announces its Interim Results for the six months ended 30 June 2010.  The Group trades through four operating subsidiaries: Clinical Computing UK Limited in the United Kingdom and Europe, Clinical Computing Inc. in the United States, Clinical Computing Pty Limited in Australia and Hydra Management Limited ("Hydra") in the United Kingdom.

Financial Highlights

·     Total revenue of £1,517,767 (H1 2009: £1,528,439)

·     Recurring maintenance revenues decreased 5.8% to £833,675 (H1 2009: £884,969)

·     Operating costs decreased 8.9% to £1,606,367 (H1 2009: £1,762,795)

·     Loss from operations reduced to £88,600 (H1 2009: £234,356)

·     R&D tax credit of £240,377 (H1 2009: £394,183)

·     Profit after tax of £144,185 (H1 2009: profit of £154,550)

·     Earnings per share of 0.1p (H1 2009: earnings 0.1p)

·     EBITDA positive £3,877 (H1 2009: negative £145,405)

·     Positive cash flow from operating activities £282,345 (H1: 2009 negative £36,669)

Operational Highlights

·     First US clinicalvision V hosted contract secured

·     First French-Canadian clinicalvision V site goes live

·     Two NHS Trusts signed contracts for clinicalvision V

·     Seven implementations of clinicalvision V underway and anticipating one go-live per month for remainder of 2010

·     11 new contracts signed by Hydra business

·     Strong customer loyalty with majority of orders placed from existing Hydra customers

·     Successful Launch of Hydra Manager V7 at Hydra User Group

Outlook

Chairman Howard Kitchner, commenting on the Group outlook, said:

"On the back of positive operating cash flow, positive EBITDA and after tax profitability the Group's balance sheet continues to strengthen organically. The two operating subsidiaries are positioned to continue to deliver improving operating results.

The Hydra business backlog is relatively strong for the near term and the Clinical business is positioned to expand from its footprint of clinicalvision V reference customers."

Contacts:
Joe Marlovits, Chief Executive Clinical Computing Plc www.ccl.com	020 3006 7536
Simon Sacerdoti Cairn Financial Advisers LLP  - Nominated Adviser	020 7148 7900

 

 

 

CHAIRMAN'S STATEMENT

 

Introduction

 

We are pleased to report our interim results for the six month period to 30 June 2010.  The Group continues its recent positive financial trends with respect to operating results, profitability and operating cash flow. These positive trends result from several successful product enhancements across both business units.  We now have reference accounts for clinicalvision V in the US, UK, Canada and French speaking Canada; additionally Hydra has recently launched version 7.0 of Hydra Manager, which increases the planning functionality of this industry leading application. During the six month period Clinical has won three new contracts and Hydra has won 11 new contracts.

Although revenues are relatively flat when compared to last year we have reduced our operating costs following the completion of clinicalvision V and are pleased to report a continued reduction in operating losses and a profit after tax of £144,185.   

Clinical business

During the period under review we are pleased to report two firsts for the business: we have secured our first US clinicalvision V hosted contract with a hospital-based customer and have completed the implementation of the first French-Canadian version of clinicalvision.  In addition we have secured two clinicalvision V contracts with NHS customers one of which is a new customer for the business. The business is now managing seven concurrent implementations for clinicalvision and we are anticipating one go-live per month for the remainder of the year.

Following the establishment of reference sites in our key markets we are actively involved in several regional tenders spread across Australia, UK and the US which we believe will be decided in the second half of 2010. Additionally we are working to capitalise on the footprint we have developed in the Canadian market.

Since the release of clinicalvision V we have been reducing our overall investment in research and development and for the period under review we are reporting a six month cost run-rate reduction of 15.7%. The reduction in costs has resulted in an improvement in operating performance of the business and we are reporting a business line operating loss of £81,538 (H1 2009: £143,896). During the period under review we have seen a reduction in maintenance revenue when compared to the prior year, however, we expect this trend to reverse in the second half as we manage the above noted clinicalvision contracts through to go-live and transition these accounts to maintenance contracts.

Hydra business

During the period under review we are pleased to report a 52.3% increase in revenue to £442,870 (H1 2009: £290,870). The business has won a number of new contracts in the period with public sector bodies, local authorities, nationalised businesses and emergency services providers. In addition a number of blue chip private sector businesses have chosen Hydra in competitive bid situations. These organisations cover a range of sectors and include insurance, marketing, software and entertainment.

The depth and breadth of features and stability of the Hydra Software combined with fast implementation times have proved to be key reasons why customers have been selecting Hydra over other alternatives.

During the period the business also launched its V7 version of the product at its Annual User Group Forum. Extensive market research was used as part of the design of V7 resulting in enhanced planning features and reporting capabilities. There has been strong interest in the new version which is due for release in the fourth quarter of this year.

The Hydra Manager application assists organisations in improving efficiencies and delivering against budget and automatically produces key information regarding the performance of portfolios, projects and resources. In the current economic climate businesses are seeking efficiency improvements and Hydra Manager is a key tool in managing the delivery of these improvements.

The combination of the market, product strengths and short payback period has contributed to the revenue growth and profits generated by Hydra in the period. Hydra operating profit was £78,851 (2009 H1: loss £8,693).

Financial results

Group revenue of £1,517,767 was consistent with the amount reported for the same period in the prior year (H1 2009: £1,528,439).

The revenue mix by business was:

70.8% Clinical business or revenues of £1,074,897 (H1 2009: £1,237,569 and 81%)

29.2% Hydra business or revenues of £442,870 (H1 2009: £290,870 and 19%).

Recurring maintenance revenues accounted for 54.9% (H1 2009: 57.9%) of our total revenues and decreased 5.8% to £833,675 (H1 2009: £884,969). The decrease in maintenance revenues is attributed to the Clinical business's Proton customers not renewing maintenance contracts at the same rate as prior years.  Proton has been superseded by clinicalvision V and we are actively working to upgrade this customer base.     

The Group's operating costs continue to decrease as we adjust our operating structure away from research and development. Total operating costs have decreased 8.9% to £1,606,367 (H1 2009: £1,762,795). We anticipate a further decline to operating costs during the second half of 2010.

The operating costs are attributed to business unit as follows:

72.0% Clinical business or £1,156,435 (H1 2009: £1,381,465 and 78.4%)

22.7% Hydra business or £364,019 (H1 2009: £299,563 and 17%)

5.3% Parent company costs were £85,913 (H1 2009: £81,767 and 4.6%).

Loss from operations improved to £88,600 (H1 2009: loss £234,356) and are shown below by business line:

Clinical business operating loss £81,538 (H1 2009: loss £143,896)

Hydra business operating profit £78,851 (H1 2009: loss £8,693)

Parent Company operating loss £85,913 (H1 2009: loss £81,767) 

As in prior years the Group continues to develop its core technologies: clinicalvision and Hydra Manager. This development effort has resulted in the Group receiving R&D tax credits under the United Kingdom R&D tax credit regime. For the year under review the Group has received £240,377 of tax credits for research and development activities undertaken in 2009 (H1 2009: R&D tax credit of £394,183 for research and development undertaken in 2008, 2007 and 2006).  

The Group is reporting a profit after tax of £144,185 for the period (H1 2009: profit £154,550). Earnings per share for the period under review are 0.1p (H1 2009: earnings per share of 0.1p).

EBITDA for the first half 2010 was a positive £3,877 compared to a negative £145,504 in the first half of 2009. The non-cash charge for depreciation and amortisation for the first half of 2010 was £92,477 (H1 2009: £88,951). This is the second consecutive six month period in which the Group has reported positive EBITDA.

Likewise, we are also reporting the second consecutive six month period of positive cash flow from operating activities. Operating cash flows were £282,345 for the period under review (H1 2009: negative 36,669) and were a positive £256,171 in the second half of 2009.

During the twelve month period ending 30 June 2010 the Group increased its borrowings by £52,220.  The Group's debt facilities amount to £930,000, of which £734,687 was drawn at 30 June 2010.  Consequently at 30 June 2010 there were undrawn facilities of £195,313, in addition to the cash balance of £847,859.  Given the above cash resources, the Group's operational performance and order book, and its forecasts and projections, it should be able to operate within the level of the above noted facilities. As a consequence, the directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future.

Outlook

On the back of positive operating cash flow, positive EBITDA and after tax profitability the Group's balance sheet continues to strengthen organically. The two operating subsidiaries are positioned to continue to deliver improving operating results.

The Hydra business backlog is relatively strong for the near term and the Clinical business is positioned to expand from its footprint of clinicalvision V reference customers.

Against this, and balanced against general market conditions, we are cautiously optimistic that we will sustain our recent positive financial trends.

Howard Kitchner

Chairman

13 August 2010

 

Unaudited condensed consolidated income statement

Six months ended 30 June 2010

			Audited
	Six months	Six months	year
	ended	ended	ended
	30 June 2010	30 June 2009	31 December 2009
	£	£	£
Continuing operations
Total revenue (Note 3)	1,517,767	1,528,439	3,179,365
Cost of sales	(365,956)	(366,532)	(805,487)
	--------------	--------------	-----------------
Gross profit	1,151,811	1,161,907	2,373,878
Distribution costs	(155,132)	(141,004)	(330,578)
Administrative expenses
Research and development	(654,947)	(758,012)	(1,341,838)
Other	(430,332)	(497,247)	(921,147)
Total administrative expenses	(1,085,279)	(1,255,259)	(2,262,985)
	--------------	-------------	-----------------
Loss from operations	(88,600)	(234,356)	(219,685)
Finance income	101	1,327	1,506
Finance expense	(7,693)	(6,604)	(14,453)
	--------------	------------	-----------------
Loss before tax	(96,192)	(239,633)	(232,632)
Income tax credit (Note 4)	240,377	394,183	453,026
	--------------	------------	-----------------
Profit for the period attributable to equity holders of the company	144,185	154,550	220,394
	--------------	------------	----------------
Basic earnings per share (Note 5)	0.1p --------------	0.1p ------------	0.2p ----------------
Diluted earnings per share (Note 5)	0.1p --------------	0.1p --------------	0.2p ----------------

The notes form part of this condensed financial information.

Unaudited condensed consolidated statement of comprehensive income

Six months ended 30 June 2010

			Audited
	Six months	Six months	Year
	ended	Ended	Ended
	30 June 2010	30 June 2009	31 December 2009
	£	£	£
Profit for the period	144,185	154,550	220,394
Exchange differences on translating foreign operations	(37,333)	19,621	(22,521)
	-------------	-------------	----------------
Total comprehensive income for the period	106,852	174,171	197,873
	-------------	-------------	----------------

The notes form part of this condensed financial information.

Unaudited condensed consolidated statement of financial position

30 June 2010

	30 June	30 June	Audited 31 December
	2010	2009	2009
	£	£	£
Non-current assets
Intangible assets	257,444	365,960	309,426
Goodwill	157,658	157,658	157,658
Property, plant and equipment	60,485	94,861	78,269
	-------------	---------------	------------
	475,587	618,479	545,353
	-------------	---------------	------------
Current assets
Trade and other receivables	530,857	722,002	450,574
Cash and cash equivalents	847,859	260,794	551,404
	-------------	---------------	------------
	1,378,716	982,796	1,001,978
	-------------	---------------	------------
Total assets	1,854,303	1,601,275	1,547,331
	-------------	---------------	------------
Current liabilities
Trade and other payables	(1,278,011)	(1,239,456)	(1,103,626)
Bank loans	(734,687)	(682,467)	(726,664)
	-------------	---------------	-------------
	(2,012,6998)	(1,921,923)	(1,830,290)
	-------------	---------------	---------------
Net liabilities	(158,395)	(320,648)	(282,959)
	-------------	---------------	-------------
Equity
Share capital	2,433,251	2,433,251	2,433,251
Share premium account	7,750,957	7,750,957	7,750,957
Share option reserve	142,393	110,694	124,681
Translation reserve	(31,710)	47,765	5,623
Retained earnings	(10,453,286)	(10,663,315)	(10,597,471)
	-------------	---------------	-----------------
Shareholders' funds - deficit (Note 6)	(158,395)	(320,648)	(282,959)
	-------------	--------------	------------

The notes form part of this condensed financial information.

 

Unaudited condensed consolidated statement of cash flow

Six months ended 30 June 2010

			Audited
	Six months	Six months	year
	ended	ended	ended
	30 June 2010	30 June 2009	31 December 2009
	£	£	£
Net cash from operating activities (Note 7)	282,345	(36,669)	219,502
Investing activities
Interest received	101	1,327	1,506
Purchases of property, plant and equipment	(2,676)	(4,042)	(12,203)
	---------------	---------------	--------------
Net cash used in investing activities	(2,575)	(2,715)	(10,697)
	---------------	---------------	--------------
Financing activities
Increase in bank loan	8,023	9,712	53,909
	---------------	---------------	---------------
Net cash from financing activities	8,023	9,712	53,909
	---------------	---------------	---------------
Net increase/(decrease) in cash and cash equivalents	287,793	(29,672)	262,714
Cash and cash equivalents at beginning of period	551,404	299,188	299,188
Effect of foreign exchange rate changes	8,662	(8,722)	(10,498)
	---------------	---------------	----------------
Cash and cash equivalents at end of period	847,859	260,794	551,404
	---------------	---------------	---------------

The notes form part of this condensed financial information.

NOTES:

1. Basis of preparation

The accounting policies applied in the unaudited condensed interim financial statements have been prepared in conformity with recognition and measurement principles required by International Financial Reporting Standards ("IFRS") in issue and as adopted by the European Union and are effective or are expected to be adopted and effective at 31 December 2010. The unaudited financial statements have been prepared using accounting policies consistent in all material respects with those applied in the Group's Annual Report for the year ended 31 December 2009 and consistent with those that will be applied during the year ended 31 December 2010. The financial information provided herein should be read in connection with the Group's audited Consolidated Financial Statements and the notes thereto for the year ended 31 December 2009.

The Group is marginally loss making at the operational level. The directors continue to monitor management's forecasts for revenues, costs and working capital needs on a regular basis. Although these projections show improving trading conditions, inherently there can be no certainty that these forecasts will be achieved. Following a review of the above noted forecasts and taking into account available borrowing facilities, the directors have formed a judgement, at the time of approving this interim announcement, that there is reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future.

This interim report does not constitute statutory accounts of the Group within the meaning of section 435 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2009 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain a statement under section 498 of the Companies Act 2006.

2.     Business and geographic segments

		Unaudited six months	Unaudited six months	Audited year
		ended	ended	ended
		30 June	30 June	31 December
		2010	2009	2009
		£	£	£
	Revenue by segment
	Clinical business UK	406,502	342,668	602,916
	Clinical business USA	627,480	861,713	1,747,973
	Clinical business Australia	40,915	33,188	77,465
	Hydra business	442,870	290,870	751,011
		---------------	---------------	----------------
		1,517,767	1,528,439	3,179,365
		---------------	----------------	----------------

3.         Revenue 

		Unaudited six months	Unaudited six months	Audited year
		Ended	Ended	Ended
		30 June	30 June	31 December
		2010	2009	2009
		£	£	£
	Revenue by type
	Software licences	506,747	466,872	1,016,954
	Maintenance	833,675	884,969	1,716,862
	Services and other revenue	177,345	176,598	445,549
		-------------	-------------	--------------
	Revenue	1,517,767	1,528,439	3,179,365
		-------------	-------------	--------------

4.     Tax

The tax credits of £240,377 for the first half 2010 were derived from activities under taken in 2009. The tax credits of £394,183 for the half year ended 30 June 2009 included credits for R&D undertaken in 2006 and 2007 of £192,970 and tax credits for R&D undertaken in 2008 of £201,213. The Group accounts for research and development tax credits when there is sufficient certainty over receipt of the amounts involved, which is generally, when the claim has been filed with the applicable tax authority.

5.     Earnings per share

The calculation of the basic and diluted earnings per share is based on the following data:

		Unaudited six months	Unaudited six months	Audited year
		ended	ended	ended
		30 June	30 June	31 December
		2010	2009	2009
		£	£	£
	Earnings for the purposes of basic and diluted earnings per share	144,185	154,550	220,394
		---------------	---------------	---------------
		Number	Number	Number
	Weighted average number of ordinary shares used in basic earnings per share calculation	110,883,694	110,883,694	110,883,694
	Dilutive share options	-	467,831	1,149,833
		---------------	---------------	---------------
	Weighted average number of shares used in diluted earnings per share calculation	110,883,694	111,351,525	112,033,527
		---------------	---------------	---------------

6.     Unaudited condensed consolidated statement of changes in equity

			Share
	Share	Share	option	Translation	Retained	Shareholders'
	capital	premium	reserve	reserve	losses	funds
	£	£	£	£	£	£
At 31 December 2008	2,433,251	7,750,957	97,588	28,144	(10,817,865)	(507,925)
Share options	-	-	27,093	-	-	27,093
Translation of foreign operations	-	-	-	(22,521)	-	(22,521)
Profit for the year	-	-	-	-	220,394	220,394
	-------------	------------	-----------	-----------	--------------	---------------
At 31 December 2009	2,433,251	7,750,957	124,681	5,623	(10,597,471)	(282,959)
	-------------	------------	----------	-----------	--------------	---------------
Share options	-	-	17,712	-	-	17,712
Translation of foreign operations	-	-	-	(37,333)	-	(37,333)
Profit for the period	-	-	-	-	144,185	144,185
	-------------	------------	-----------	-----------	--------------	---------------
At 30 June 2010	2,433,251	7,750,957	142,393	(31,710)	(10,453,286)	(158,395)
	------------	------------	---------	-----------	--------------	---------------

			Share
	Share	Share	option	Translation	Retained	Shareholders'
	capital	premium	reserve	reserve	losses	funds
	£	£	£	£	£	£
At 31 December 2008	2,433,251	7,750,957	97,588	28,144	(10,817,865)	(507,925)
Share options	-	-	13,106	-	-	13,106
Translation of foreign operations	-	-	-	19,621	-	19,621
Profit for the period	-	-	-	-	154,550	154,550
	-------------	------------	-----------	-----------	--------------	---------------
At 30 June 2009	2,433,251	7,750,957	110,694	47,765	(10,663,315)	(320,648)
	------------	------------	---------	-----------	--------------	---------------

7.	Reconciliation of operating loss to operating cash flows

	Unaudited six months	Unaudited six months	Audited  year
	ended	ended	ended
	30 June 2010	30 June 2009	31 December 2009
	£	£	£

Loss from operations	(88,600)	(234,356)	(219,685)
Adjustments for:
Depreciation of property, plant and equipment	22,783	28,338	54,527
Share option charges	17,712	13,106	27,093
Amortisation of intangible assets	51,982	47,507	104,040
	--------------	----------------	----------------
Operating cash flows before movements in working capital	(3,877)	(145,405)	(34,025)
Increase in receivables	(85,691)	(64,405)	(23,828)
Increase/(decrease) in payables	131,475	(15,225)	(161,218)
	--------------	----------------	-----------------
Cash generated/(used) by operations	41,907	(223,035)	(219,071)
Tax credits received	240,377	192,970	453,026
Interest paid	(7,693)	(6,604)	(14,453)
	---------------	----------------	-----------------
Net cash inflow/(outflow) from operating activities	282,345 ---------------	(36,669) ----------------	219,502 -----------------

 

END

 

 

IR DGGDIBSBBGGD